Skip to main content

Table 3 Severe and fatal infectious events with EGFR-MoAbs by specific types

From: Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

  Infectious events, number/total, number RR (95%CI) Pvalue
EGFR-MoAbs Control
Severe infections     
 Unspecified 236/2844 144/2829 1.57 (1.16 to 2.13) 0.004
 Specified 365/7450 294/7347 1.18 (0.95 to 1.47) 0.14
 Febrile neutropenia 287/4551 221/4579 1.09 (0.86 to 1.38) 0.68
 Pneumonia 45/1605 37/1527 1.11 (0.72 to 1.70) 0.64
 Sepsis 33/1294 6/1241 4.30 (1.80 to 10.27) 0.001
Fatal infections     
 Unspecified 8/1471 2/1424 2.39 (0.58 to 9.83) 0.23
 Specified 16/2486 9/2305 1.43 (0.64 to 3.18) 0.38
 Pneumonia 6/1336 3/1261 1.46 (0.39 to 5.48) 0.56
 Febrile neutropenia 1/321 1/321 1.00 (0.11 to 9.51) 1.00
 Sepsis 9/829 5/732 1.54 (0.50 to 4.74) 0.45
  1. CI, confidence interval; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; RR, relative risk.